Prevalence of the metabolic syndrome in an incident dialysis population

Daniel O. Young, Richard J. Lund, Gleb Haynatzki, Robert W. Dunlay

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The National Heart, Lung, and Blood Institute's National Cholesterol Education Program 2001 Adult Treatment Panel III report defined the metabolic syndrome as having at least 3 of the following 5 criteria: abdominal obesity, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, an elevated blood pressure, and an elevated fasting glucose. Evidence is accumulating to suggest that the metabolic syndrome predisposes to cardiovascular disease (CVD). End-stage kidney disease (ESKD) patients requiring dialysis have a substantially elevated risk of CVD morbidity and mortality. Dialysis patients' increased risk can be partially explained by traditional and nontraditional risk factors. The prevalence of the metabolic syndrome in dialysis patients is unknown. This retrospective, cross-sectional study of 202 incident dialysis patients examined the prevalence of the metabolic syndrome at the time of renal replacement therapy initiation. The study group was compared with all incident dialysis patients in 2002 on file with the U.S. Renal Data System. Females represented 39.1% of the study population. Blacks composed 34.7% of the study group. Diabetes was the etiology of ESKD in 44.6% of our patients. Surrogate criteria were used for the Adult Treatment Panel III risk factors of abdominal obesity and elevated fasting glucose levels. Overall, the prevalence of the metabolic syndrome was 69.3% in our population and was especially prevalent among diabetic, female, and white ESKD patients. Study limitations included the use of surrogate markers for 2 criteria of the metabolic syndrome and dependence on the Medical Evidence Report (Form 2728) for baseline characteristics. In summary, the metabolic syndrome is highly prevalent in incident dialysis patients.

Original languageEnglish (US)
Pages (from-to)86-95
Number of pages10
JournalHemodialysis International
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Dialysis
Population
Chronic Kidney Failure
Abdominal Obesity
Fasting
Cardiovascular Diseases
National Heart, Lung, and Blood Institute (U.S.)
Glucose
Renal Replacement Therapy
Information Systems
LDL Cholesterol
HDL Cholesterol
Triglycerides
Cross-Sectional Studies
Biomarkers
Cholesterol
Blood Pressure
Morbidity
Kidney
Education

Keywords

  • ATP III
  • Cardiovascular disease morbidity and mortality
  • End-stage kidney disease
  • Incident dialysis patients
  • Metabolic syndrome

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Prevalence of the metabolic syndrome in an incident dialysis population. / Young, Daniel O.; Lund, Richard J.; Haynatzki, Gleb; Dunlay, Robert W.

In: Hemodialysis International, Vol. 11, No. 1, 01.01.2007, p. 86-95.

Research output: Contribution to journalArticle

Young, Daniel O. ; Lund, Richard J. ; Haynatzki, Gleb ; Dunlay, Robert W. / Prevalence of the metabolic syndrome in an incident dialysis population. In: Hemodialysis International. 2007 ; Vol. 11, No. 1. pp. 86-95.
@article{02fc0ed2d99d4232bcdd9ce249d7cf7f,
title = "Prevalence of the metabolic syndrome in an incident dialysis population",
abstract = "The National Heart, Lung, and Blood Institute's National Cholesterol Education Program 2001 Adult Treatment Panel III report defined the metabolic syndrome as having at least 3 of the following 5 criteria: abdominal obesity, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, an elevated blood pressure, and an elevated fasting glucose. Evidence is accumulating to suggest that the metabolic syndrome predisposes to cardiovascular disease (CVD). End-stage kidney disease (ESKD) patients requiring dialysis have a substantially elevated risk of CVD morbidity and mortality. Dialysis patients' increased risk can be partially explained by traditional and nontraditional risk factors. The prevalence of the metabolic syndrome in dialysis patients is unknown. This retrospective, cross-sectional study of 202 incident dialysis patients examined the prevalence of the metabolic syndrome at the time of renal replacement therapy initiation. The study group was compared with all incident dialysis patients in 2002 on file with the U.S. Renal Data System. Females represented 39.1{\%} of the study population. Blacks composed 34.7{\%} of the study group. Diabetes was the etiology of ESKD in 44.6{\%} of our patients. Surrogate criteria were used for the Adult Treatment Panel III risk factors of abdominal obesity and elevated fasting glucose levels. Overall, the prevalence of the metabolic syndrome was 69.3{\%} in our population and was especially prevalent among diabetic, female, and white ESKD patients. Study limitations included the use of surrogate markers for 2 criteria of the metabolic syndrome and dependence on the Medical Evidence Report (Form 2728) for baseline characteristics. In summary, the metabolic syndrome is highly prevalent in incident dialysis patients.",
keywords = "ATP III, Cardiovascular disease morbidity and mortality, End-stage kidney disease, Incident dialysis patients, Metabolic syndrome",
author = "Young, {Daniel O.} and Lund, {Richard J.} and Gleb Haynatzki and Dunlay, {Robert W.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1111/j.1542-4758.2007.00158.x",
language = "English (US)",
volume = "11",
pages = "86--95",
journal = "Hemodialysis International",
issn = "1492-7535",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prevalence of the metabolic syndrome in an incident dialysis population

AU - Young, Daniel O.

AU - Lund, Richard J.

AU - Haynatzki, Gleb

AU - Dunlay, Robert W.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The National Heart, Lung, and Blood Institute's National Cholesterol Education Program 2001 Adult Treatment Panel III report defined the metabolic syndrome as having at least 3 of the following 5 criteria: abdominal obesity, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, an elevated blood pressure, and an elevated fasting glucose. Evidence is accumulating to suggest that the metabolic syndrome predisposes to cardiovascular disease (CVD). End-stage kidney disease (ESKD) patients requiring dialysis have a substantially elevated risk of CVD morbidity and mortality. Dialysis patients' increased risk can be partially explained by traditional and nontraditional risk factors. The prevalence of the metabolic syndrome in dialysis patients is unknown. This retrospective, cross-sectional study of 202 incident dialysis patients examined the prevalence of the metabolic syndrome at the time of renal replacement therapy initiation. The study group was compared with all incident dialysis patients in 2002 on file with the U.S. Renal Data System. Females represented 39.1% of the study population. Blacks composed 34.7% of the study group. Diabetes was the etiology of ESKD in 44.6% of our patients. Surrogate criteria were used for the Adult Treatment Panel III risk factors of abdominal obesity and elevated fasting glucose levels. Overall, the prevalence of the metabolic syndrome was 69.3% in our population and was especially prevalent among diabetic, female, and white ESKD patients. Study limitations included the use of surrogate markers for 2 criteria of the metabolic syndrome and dependence on the Medical Evidence Report (Form 2728) for baseline characteristics. In summary, the metabolic syndrome is highly prevalent in incident dialysis patients.

AB - The National Heart, Lung, and Blood Institute's National Cholesterol Education Program 2001 Adult Treatment Panel III report defined the metabolic syndrome as having at least 3 of the following 5 criteria: abdominal obesity, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, an elevated blood pressure, and an elevated fasting glucose. Evidence is accumulating to suggest that the metabolic syndrome predisposes to cardiovascular disease (CVD). End-stage kidney disease (ESKD) patients requiring dialysis have a substantially elevated risk of CVD morbidity and mortality. Dialysis patients' increased risk can be partially explained by traditional and nontraditional risk factors. The prevalence of the metabolic syndrome in dialysis patients is unknown. This retrospective, cross-sectional study of 202 incident dialysis patients examined the prevalence of the metabolic syndrome at the time of renal replacement therapy initiation. The study group was compared with all incident dialysis patients in 2002 on file with the U.S. Renal Data System. Females represented 39.1% of the study population. Blacks composed 34.7% of the study group. Diabetes was the etiology of ESKD in 44.6% of our patients. Surrogate criteria were used for the Adult Treatment Panel III risk factors of abdominal obesity and elevated fasting glucose levels. Overall, the prevalence of the metabolic syndrome was 69.3% in our population and was especially prevalent among diabetic, female, and white ESKD patients. Study limitations included the use of surrogate markers for 2 criteria of the metabolic syndrome and dependence on the Medical Evidence Report (Form 2728) for baseline characteristics. In summary, the metabolic syndrome is highly prevalent in incident dialysis patients.

KW - ATP III

KW - Cardiovascular disease morbidity and mortality

KW - End-stage kidney disease

KW - Incident dialysis patients

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=33846343251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846343251&partnerID=8YFLogxK

U2 - 10.1111/j.1542-4758.2007.00158.x

DO - 10.1111/j.1542-4758.2007.00158.x

M3 - Article

VL - 11

SP - 86

EP - 95

JO - Hemodialysis International

JF - Hemodialysis International

SN - 1492-7535

IS - 1

ER -